ClinicalTrials.gg
CompletedNCT03566810Updated Jan 9, 2020Results posted

Glucophage Extended Release (GXR) China Bioequivalence Study (Nantong - Darmstadt)

A Phase 1 interventional study of Test GXR and Reference GXR in Healthy, sponsored by Merck KGaA, Darmstadt, Germany. Completed at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-01-09.

Sponsored by Merck KGaA, Darmstadt, Germany · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
54
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 113 studies testing metformin in Diabetes Mellitus — 7 open to participants now, 7 under way, 1 of them phase 3. Metformin · Diabetes Mellitus.

Enrollment
75th of 112
54 · median 108
Started
2018
with 3 others
Phase 1
15 of 113
2 open now
Registered
96th of 113
by date
Lead sponsor
3 of 113
Merck KGaA, Darmstadt, Germany

Among the 113 studies testing metformin in Diabetes Mellitus, this one is the 75th largest by enrollment of the 112 interventional ones that give a count, is one of 4 that started in 2018, is one of 15 in phase 1, and was the 96th registered.

Diabetes Mellitus

8,293 studies on the registry are indexed under Diabetes Mellitus; 1,072 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

7 of the 113 studies testing metformin in Diabetes Mellitus are open now, in 6 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About metformin

Metformin: first FDA approval 1995 (GLUCOPHAGE), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 648 Diabetes Mellitus studies recruiting now, 357 (55%) set no upper age limit and 195 (30%) stop at 75 or younger; 88 take children under 18; 182 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 113 studies testing metformin in Diabetes Mellitus, or all of them as a file.
02

Study summary

The study will assess the bioequivalence between single doses of GXR manufactured in Merck Nantong China (test drug) and GXR manufactured in Merck Darmstadt Germany (reference drug) under fed and fasted state in healthy participants.

03

Conditions studied

  • Healthy

Browse trials for

Keywords

  • Diabetes Mellitus
  • Glucophage Extended Release (GXR)
  • Bioequivalence Study
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Overtly healthy as determined by medical evaluation, including medical history and a physical examination
  • Have a body weight within 50 to 90 kilogram (kg) and (BMI) within the range 18 to 30 kg per meter square (kg/m\^2) (inclusive)
  • Chinese male and female (at least 1/4 of each gender per study group)
  • A male participant must agree to use and to have their female partners use a highly effective (that is, methods with a failure rate of less than 1 percent per year) for a period of at least 1 month before and after dosing
  • A female is eligible if she is not pregnant (that is, after a confirmed menstrual period and a negative serum pregnancy test), not breastfeeding, and at least one of the following conditions applies
  • Is not a woman of (WOCBP) OR
  • Is a WOCBP who agrees to use a highly effective contraceptive method (that is, has a failure rate of less than 1 percent per year) for a period of at least 1 month before and after dosing
  • Can give signed , which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and this protocol
  • Non-smoker (0 cigarettes, pipes, cigars, or others) since at least 3 months
  • All values for biochemistry and hematology tests of blood and urine within the normal range or showing no deviation as judged by the Investigator
  • recording (12 lead ECG) without signs of clinically relevant pathology as judged by the Investigator.
  • Pulse, body temperature, and respiration in sitting position within the normal range or showing no clinically relevant deviation as judged by the Investigator. Blood pressure in sitting position within normal range: greater than or equals to (>=) 90 millimeter of mercury (mmHg) and less than or equal to (=\<) 139 mmHg for systolic blood pressure; >= 60 mmHg and =\< 90 mmHg for diastolic blood pressure
  • Negative screen for alcohol and drugs of abuse (cannabis, benzodiazepines, barbiturates, opiates, cocaine, and methyl amphetamine) at screening and on admission
  • Negative screen for hepatitis A virus (HAV) antibodies, surface antigen (HBsAg), virus (HCV) antibodies, (HIV) antibodies, and Treponema pallidum (TP) antibodies

Exclusion criteria

Exclusion Criteria:

  • Participation in a clinical trial within 90 days prior to first drug administration
  • Blood donation (equal or more than 500 milliliter [mL]) or significant blood loss within 90 days prior to first drug administration
  • Any surgical or medical condition, including findings in the medical history or in the pre-study assessments, or any other significant disease, that in the opinion of the Investigator, constitutes a risk or a for the participation of the participant in the study or that could interfere with the study objectives, conduct or evaluation
  • History of surgery of the gastrointestinal tract which could influence the gastrointestinal absorption and/or motility according to the Investigator's opinion
  • History or presence of relevant liver diseases or hepatic dysfunction.
  • Allergy: ascertained or presumptive to the active drug substance and/or formulations' ingredients; history of anaphylaxis to drugs or allergic reactions in general, which the Investigator considers may affect the outcome of the study
  • Receipt of any prescription or non-prescription medication within 2 weeks before the first medicinal product (IMP) administration, including multivitamins and herbal products (that is St John's Wort, or traditional Chinese medicines), except for the permitted medications
  • Renal failure or renal dysfunction ( [Ccr] \< 80 mL/minute) as assessed by using the estimated measure with the Cockcroft-Gault equation.
  • Known lack of participant compliance or inability to communicate or cooperate with the Investigator (example, language problem, poor mental status)
  • Non-acceptance of study high-fat breakfast (example, vegetarians, vegans and participants who follow special diets)
  • Consumption of large quantities of methylxanthine-containing beverages (>5 cups of coffee/day or equivalent)
  • Consumption of grapefruit, cranberry, or juices of these fruits, from 14 days prior to drug administration until collection of the last Pharmacokinetics sample in Period 2
  • Any contraindication to Glucophage
  • Abnormal and chest X-ray finding at screening
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
54 participants (actual)

Study arms

  • Experimental
    First Test GXR (Fasting), Then Reference GXR (Fasting)

    Participants received a single oral dose of 500 milligrams (mg) of test GXR tablet (Merck Nantong/China) on Day 1 in treatment period 1 followed by a single oral dose of 500 mg reference GXR (Merck Darmstadt/Germany) on Day 8 in treatment period 2 under fasting conditions. There was a wash-out period of 7 days between each treatment period.

    Drug: Test GXR · Drug: Reference GXR

  • Experimental
    First Reference GXR (Fasting), Then Test GXR (Fasting)

    Participants received a single oral dose of 500 mg of reference GXR tablet (Merck Darmstadt/Germany) on Day 1 in treatment period 1 followed by a single oral dose of 500 mg test GXR (Merck Nantong/China) on Day 8 in treatment period 2 under fasting conditions. There was a wash-out period of 7 days between each treatment period.

    Drug: Test GXR · Drug: Reference GXR

  • Experimental
    First Test GXR (Fed), Then Reference GXR (Fed)

    Participants received a single oral dose of 500 mg of test GXR tablet (Merck Nantong/China) on Day 1 in treatment period 1 followed by a single oral dose of 500 mg reference GXR (Merck Darmstadt/Germany) on Day 8 in treatment period 2 under fed conditions. There was a wash-out period of 7 days between each treatment period.

    Drug: Test GXR · Drug: Reference GXR

  • Experimental
    First Reference GXR (Fed), Then Test GXR (Fed)

    Participants received a single oral dose of 500 mg of reference GXR tablet (Merck Darmstadt/Germany) on Day 1 in treatment period 1 followed by a single oral dose of 500 mg test GXR (Merck Nantong/China) on Day 8 in treatment period 2 under fed conditions. There was a wash-out period of 7 days between each treatment period.

    Drug: Test GXR · Drug: Reference GXR

Interventions

  • Participants received a single oral dose of 500 mg of test GXR tablet (Merck Nantong/China) under fasting or fed conditions on either Day 1 (Treatment Period 1) or Day 8 (Treatment Period 2).

    Also known as: Metformin hydrochloride

  • Participants received a single oral dose of 500 mg of reference GXR tablet (Merck Darmstadt/France) under fasting or fed conditions on either Day 1 (Treatment Period 1) or Day 8 (Treatment Period 2).

    Also known as: Metformin hydrochloride

06

What researchers measure

Primary outcomes

  1. Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Sampling Time (AUC 0-t) of Metformin

    Area under the plasma concentration versus time curve from time zero to the last sampling time t at which the concentration was at or above the lower limit of quantification (LLQ). AUC0-t was to be calculated according to the mixed log-linear trapezoidal rule.

    Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14 post-dose on Day 1 and Day 8; 24, 30, 36 hours post-dose on Day 2 and 9; 48 hours post-dose on Day 3 and 10

  2. Maximum Observed Plasma Concentration (Cmax) of Metformin

    Pharmacokinetic (PK) parameter Cmax was obtained directly from the concentration versus time curve.

    Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14 post-dose on Day 1 and Day 8; 24, 30, 36 hours post-dose on Day 2 and 9; 48 hours post-dose on Day 3 and 10

Secondary outcomes

  1. Time to Reach Maximum Plasma Concentration of Metformin

    Time to reach the maximum plasma concentration (Tmax) was obtained directly from the concentration versus time curve.

    Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14 post-dose on Day 1 and Day 8; 24, 30, 36 hours post-dose on Day 2 and 9; 48 hours post-dose on Day 3 and 10

  2. Apparent Terminal Half-Life (t1/2) of Metformin

    Terminal half-life is the time measured for the concentration to decrease by one half. Terminal half-life calculated by natural log 2 divided by lambda z.

    Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14 post-dose on Day 1 and Day 8; 24, 30, 36 hours post-dose on Day 2 and 9; 48 hours post-dose on Day 3 and 10

  3. Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity (AUC0-inf) of Metformin

    AUC0-inf was calculated by combining AUC0-t and AUCextra. AUC extra represents an extrapolated value obtained by Clast/ lambda z, where Clast is the calculated plasma concentration at the last sampling time point at which the measured plasma concentration is at or above the Lower Limit of quantification (LLQ) and lambda z is the apparent terminal rate constant determined by log-linear regression analysis of the measured plasma concentrations of the terminal log-linear phase.

    Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14 post-dose on Day 1 and Day 8; 24, 30, 36 hours post-dose on Day 2 and 9; 48 hours post-dose on Day 3 and 10

  4. Area Under the Plasma Concentration-Time Curve From Time Tlast Extrapolated to Infinity (AUCextra) of Metformin

    AUCextra% was defined as area under the curve from time tlast extrapolated to infinity as percentage of AUC 0-infinity. Here, tlast is the last sampling time at which the concentration is at or above the lower limit of quantification.

    Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14 post-dose on Day 1 and Day 8; 24, 30, 36 hours post-dose on Day 2 and 9; 48 hours post-dose on Day 3 and 10

  5. Elimination Rate Constant (Lambda z) of Metformin

    Lambda z was determined from the terminal slope of the log-transformed plasma concentration curve using linear regression method.

    Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14 post-dose on Day 1 and Day 8; 24, 30, 36 hours post-dose on Day 2 and 9; 48 hours post-dose on Day 3 and 10

  6. Total Body Clearance (CL/f) of Metformin

    Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes.

    Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14 post-dose on Day 1 and Day 8; 24, 30, 36 hours post-dose on Day 2 and 9; 48 hours post-dose on Day 3 and 10

  7. Apparent Volume of Distribution at After Extravascular Administration (Vz/f) of Metformin

    Vz/f is defined as the distribution of a study drug between plasma and the rest of the body after oral dosing.

    Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14 post-dose on Day 1 and Day 8; 24, 30, 36 hours post-dose on Day 2 and 9; 48 hours post-dose on Day 3 and 10

  8. Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs

    An Adverse event (AE) was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease associated with the use of study drug, whether or not considered related to the study drug or worsening of pre-existing medical condition, whether or not related to study drug. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. An AE was considered as 'treatment emergent' if it occurred after the first drug administration of each period or if it was present prior to drug administration but exacerbated after the drug administration. TEAEs included both Serious TEAEs and non-serious TEAEs.

    Time frame: Time from informed consent up to end of study (Day 15)

  9. Number of Participants With Clinically Significant Abnormalities in Vital Signs

    Vital sign assessment included blood pressure, pulse rate, body temperature and respiration (frequency per minute). Number of participants with clinically significant abnormalities in vital signs were reported. Clinically significance was decided by investigator.

    Time frame: Time from informed consent up to end of study (Day 15)

  10. Number of Participants With Clinically Significant Abnormalities in Laboratory Values

    The laboratory measurements included hematology, blood chemistry and urinalysis. Number of participants with clinically significant abnormalities in laboratory values were reported. Clinically Significance was decided by investigator.

    Time frame: Time from informed consent up to end of study (Day 15)

  11. Number of Participants With Clinically Significant Abnormalities in Physical Examination Findings

    Physical examination included assessments of the general appearance, skin and mucosa, superficial lymph nodes, head and neck, chest, abdomen, musculoskeletal, and neurological systems. Number of participants with clinically significant abnormalities in physical examination findings were reported. clinically significance was decided by investigator.

    Time frame: Time from informed consent up to end of study (Day 15)

  12. Number of Participants With Clinically Significant Abnormalities in 12-lead Electrocardiogram (ECG) Findings

    The 12-lead ECG recordings were obtained after 5 minutes of rest in a semi-supine position. ECG recordings included rhythm, ventricular rate, PR interval, QRS duration, QT and QTc intervals. Number of participants with clinically significant abnormalities in 12-lead ECG findings were reported. Clinically significance was decided by investigator.

    Time frame: Time from informed consent up to end of study (Day 15)

07

Results

Posted Jan 9, 2020

Participant flow

Treatment Period 1 (Day 1-Day 3)
Participant flow — Treatment Period 1 (Day 1-Day 3)
MilestoneFirst Test GXR (Fasting), Then Reference GXR (Fasting)First Reference GXR (Fasting), Then Test GXR (Fasting)First Test GXR (Fed), Then Reference GXR (Fed)First Reference GXR (Fed), Then Test GXR (Fed)
Started191988
Treated191888
Completed191888
Not completed0100
Withdrew: Enrolled, but never treated0100
Treatment Period 2 (Day 8- Day 10)
Participant flow — Treatment Period 2 (Day 8- Day 10)
MilestoneFirst Test GXR (Fasting), Then Reference GXR (Fasting)First Reference GXR (Fasting), Then Test GXR (Fasting)First Test GXR (Fed), Then Reference GXR (Fed)First Reference GXR (Fed), Then Test GXR (Fed)
Started191888
Completed191888
Not completed0000

Outcome measures

PrimaryArea Under the Plasma Concentration-Time Curve From Time Zero to the Last Sampling Time (AUC 0-t) of Metformin

Area under the plasma concentration versus time curve from time zero to the last sampling time t at which the concentration was at or above the lower limit of quantification (LLQ). AUC0-t was to be calculated according to the mixed log-linear trapezoidal rule.

Time frame:
Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14 post-dose on Day 1 and Day 8; 24, 30, 36 hours post-dose on Day 2 and 9; 48 hours post-dose on Day 3 and 10
Reported as:
Geometric mean · nanogram*hour per milliliter (ng*h/mL)
Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Sampling Time (AUC 0-t) of Metformin
nanogram*hour per milliliter (ng*h/mL)Test GXR (Fasting)Reference GXR (Fasting)Test GXR (Fed)Reference GXR (Fed)
Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Sampling Time (AUC 0-t) of Metformin3740 ± 31.53780 ± 26.25500 ± 17.15540 ± 18.7
Statistical analysis
  • Test GXR (Fasting) vs Reference GXR (Fasting) · Ratio of geometric least square(ls)mean%: 98.69 · 90% CI 92.20 to 105.64
  • Test GXR (Fed) vs Reference GXR (Fed) · Ratio of geometric ls mean percentage: 99.39 · 90% CI 93.15 to 106.05
PrimaryMaximum Observed Plasma Concentration (Cmax) of Metformin

Pharmacokinetic (PK) parameter Cmax was obtained directly from the concentration versus time curve.

Time frame:
Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14 post-dose on Day 1 and Day 8; 24, 30, 36 hours post-dose on Day 2 and 9; 48 hours post-dose on Day 3 and 10
Reported as:
Geometric mean · ng/mL
Maximum Observed Plasma Concentration (Cmax) of Metformin
ng/mLTest GXR (Fasting)Reference GXR (Fasting)Test GXR (Fed)Reference GXR (Fed)
Maximum Observed Plasma Concentration (Cmax) of Metformin572 ± 32.7578 ± 34.2519 ± 17.1536 ± 16.4
Statistical analysis
  • Test GXR (Fasting) vs Reference GXR (Fasting) · Ratio of geometric ls mean percentage: 98.92 · 90% CI 91.08 to 107.44
  • Test GXR (Fed) vs Reference GXR (Fed) · Ratio of geometric ls mean percentage: 96.89 · 90% CI 89.87 to 104.46
SecondaryTime to Reach Maximum Plasma Concentration of Metformin

Time to reach the maximum plasma concentration (Tmax) was obtained directly from the concentration versus time curve.

Time frame:
Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14 post-dose on Day 1 and Day 8; 24, 30, 36 hours post-dose on Day 2 and 9; 48 hours post-dose on Day 3 and 10
Reported as:
Median · hours
Time to Reach Maximum Plasma Concentration of Metformin
hoursTest GXR (Fasting)Reference GXR (Fasting)Test GXR (Fed)Reference GXR (Fed)
Time to Reach Maximum Plasma Concentration of Metformin3.00 (1.00 to 5.00)4.00 (1.00 to 5.00)6.00 (3.00 to 10.00)6.00 (5.00 to 8.00)
Statistical analysis
  • Test GXR (Fasting) vs Reference GXR (Fasting) · Median point estimate difference: 0.00 · 90% CI -0.50 to 0.00
  • Test GXR (Fed) vs Reference GXR (Fed) · Median point estimate difference: 0.00 · 90% CI -0.50 to 0.50
SecondaryApparent Terminal Half-Life (t1/2) of Metformin

Terminal half-life is the time measured for the concentration to decrease by one half. Terminal half-life calculated by natural log 2 divided by lambda z.

Time frame:
Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14 post-dose on Day 1 and Day 8; 24, 30, 36 hours post-dose on Day 2 and 9; 48 hours post-dose on Day 3 and 10
Reported as:
Geometric mean · hours
Apparent Terminal Half-Life (t1/2) of Metformin
hoursTest GXR (Fasting)Reference GXR (Fasting)Test GXR (Fed)Reference GXR (Fed)
Apparent Terminal Half-Life (t1/2) of Metformin5.80 ± 63.75.56 ± 58.45.34 ± 65.15.37 ± 99.8
SecondaryArea Under the Plasma Concentration-Time Curve From Time 0 to Infinity (AUC0-inf) of Metformin

AUC0-inf was calculated by combining AUC0-t and AUCextra. AUC extra represents an extrapolated value obtained by Clast/ lambda z, where Clast is the calculated plasma concentration at the last sampling time point at which the measured plasma concentration is at or above the Lower Limit of quantification (LLQ) and lambda z is the apparent terminal rate constant determined by log-linear regression analysis of the measured plasma concentrations of the terminal log-linear phase.

Time frame:
Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14 post-dose on Day 1 and Day 8; 24, 30, 36 hours post-dose on Day 2 and 9; 48 hours post-dose on Day 3 and 10
Reported as:
Geometric mean · ng*h/mL
Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity (AUC0-inf) of Metformin
ng*h/mLTest GXR (Fasting)Reference GXR (Fasting)Test GXR (Fed)Reference GXR (Fed)
Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity (AUC0-inf) of Metformin3890 ± 29.43980 ± 25.05630 ± 17.25750 ± 19.2
Statistical analysis
  • Test GXR (Fasting) vs Reference GXR (Fasting) · Ratio of geometric ls mean percentage: 97.89 · 90% CI 91.38 to 104.86
  • Test GXR (Fed) vs Reference GXR (Fed) · Ratio of geometric ls mean percentage: 98.08 · 90% CI 92.37 to 104.14
SecondaryArea Under the Plasma Concentration-Time Curve From Time Tlast Extrapolated to Infinity (AUCextra) of Metformin

AUCextra% was defined as area under the curve from time tlast extrapolated to infinity as percentage of AUC 0-infinity. Here, tlast is the last sampling time at which the concentration is at or above the lower limit of quantification.

Time frame:
Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14 post-dose on Day 1 and Day 8; 24, 30, 36 hours post-dose on Day 2 and 9; 48 hours post-dose on Day 3 and 10

No measurements were reported for this outcome.

SecondaryElimination Rate Constant (Lambda z) of Metformin

Lambda z was determined from the terminal slope of the log-transformed plasma concentration curve using linear regression method.

Time frame:
Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14 post-dose on Day 1 and Day 8; 24, 30, 36 hours post-dose on Day 2 and 9; 48 hours post-dose on Day 3 and 10

No measurements were reported for this outcome.

SecondaryTotal Body Clearance (CL/f) of Metformin

Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes.

Time frame:
Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14 post-dose on Day 1 and Day 8; 24, 30, 36 hours post-dose on Day 2 and 9; 48 hours post-dose on Day 3 and 10
Reported as:
Geometric mean · liter per hour
Total Body Clearance (CL/f) of Metformin
liter per hourTest GXR (Fasting)Reference GXR (Fasting)Test GXR (Fed)Reference GXR (Fed)
Total Body Clearance (CL/f) of Metformin128 ± 29.4126 ± 25.088.9 ± 17.287.0 ± 19.2
SecondaryApparent Volume of Distribution at After Extravascular Administration (Vz/f) of Metformin

Vz/f is defined as the distribution of a study drug between plasma and the rest of the body after oral dosing.

Time frame:
Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14 post-dose on Day 1 and Day 8; 24, 30, 36 hours post-dose on Day 2 and 9; 48 hours post-dose on Day 3 and 10
Reported as:
Geometric mean · liter
Apparent Volume of Distribution at After Extravascular Administration (Vz/f) of Metformin
literTest GXR (Fasting)Reference GXR (Fasting)Test GXR (Fed)Reference GXR (Fed)
Apparent Volume of Distribution at After Extravascular Administration (Vz/f) of Metformin1070 ± 75.61010 ± 61.1684 ± 65.8674 ± 93.7
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs

An Adverse event (AE) was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease associated with the use of study drug, whether or not considered related to the study drug or worsening of pre-existing medical condition, whether or not related to study drug. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. An AE was considered as 'treatment emergent' if it occurred after the first drug administration of each period or if it was present prior to drug administration but exacerbated after the drug administration. TEAEs included both Serious TEAEs and non-serious TEAEs.

Time frame:
Time from informed consent up to end of study (Day 15)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs
ParticipantsTest GXR (Fasting)Reference GXR (Fasting)Test GXR (Fed)Reference GXR (Fed)
TEAEs101134
Serious TEAEs0000
SecondaryNumber of Participants With Clinically Significant Abnormalities in Vital Signs

Vital sign assessment included blood pressure, pulse rate, body temperature and respiration (frequency per minute). Number of participants with clinically significant abnormalities in vital signs were reported. Clinically significance was decided by investigator.

Time frame:
Time from informed consent up to end of study (Day 15)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Abnormalities in Vital Signs
ParticipantsTest GXR (Fasting)Reference GXR (Fasting)Test GXR (Fed)Reference GXR (Fed)
Number of Participants With Clinically Significant Abnormalities in Vital Signs0000
SecondaryNumber of Participants With Clinically Significant Abnormalities in Laboratory Values

The laboratory measurements included hematology, blood chemistry and urinalysis. Number of participants with clinically significant abnormalities in laboratory values were reported. Clinically Significance was decided by investigator.

Time frame:
Time from informed consent up to end of study (Day 15)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Abnormalities in Laboratory Values
ParticipantsTest GXR (Fasting)Reference GXR (Fasting)Test GXR (Fed)Reference GXR (Fed)
Number of Participants With Clinically Significant Abnormalities in Laboratory Values0000
SecondaryNumber of Participants With Clinically Significant Abnormalities in Physical Examination Findings

Physical examination included assessments of the general appearance, skin and mucosa, superficial lymph nodes, head and neck, chest, abdomen, musculoskeletal, and neurological systems. Number of participants with clinically significant abnormalities in physical examination findings were reported. clinically significance was decided by investigator.

Time frame:
Time from informed consent up to end of study (Day 15)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Abnormalities in Physical Examination Findings
ParticipantsTest GXR (Fasting)Reference GXR (Fasting)Test GXR (Fed)Reference GXR (Fed)
Number of Participants With Clinically Significant Abnormalities in Physical Examination Findings0000
SecondaryNumber of Participants With Clinically Significant Abnormalities in 12-lead Electrocardiogram (ECG) Findings

The 12-lead ECG recordings were obtained after 5 minutes of rest in a semi-supine position. ECG recordings included rhythm, ventricular rate, PR interval, QRS duration, QT and QTc intervals. Number of participants with clinically significant abnormalities in 12-lead ECG findings were reported. Clinically significance was decided by investigator.

Time frame:
Time from informed consent up to end of study (Day 15)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Abnormalities in 12-lead Electrocardiogram (ECG) Findings
ParticipantsTest GXR (Fasting)Reference GXR (Fasting)Test GXR (Fed)Reference GXR (Fed)
Number of Participants With Clinically Significant Abnormalities in 12-lead Electrocardiogram (ECG) Findings0000

Adverse events

Collected over Time from informed consent up to end of study (Day 15). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Test GXR (Fasting)0/37 (0%)0/37 (0%)10/37 (27%)
Reference GXR (Fasting)0/37 (0%)0/37 (0%)11/37 (29.7%)
Test GXR (Fed)0/16 (0%)0/16 (0%)3/16 (18.8%)
Reference GXR (Fed)0/16 (0%)0/16 (0%)4/16 (25%)
Most frequent other events
Showing 10 of 21
Most frequent other events
EventTest GXR (Fasting)Reference GXR (Fasting)Test GXR (Fed)Reference GXR (Fed)
DiarrhoeaGastrointestinal disorders8/376/371/163/16
Upper respiratory tract infectionInfections and infestations0/373/370/160/16
Abdominal painGastrointestinal disorders2/370/371/160/16
NauseaGastrointestinal disorders1/370/370/161/16
Mouth ulcerationGastrointestinal disorders0/370/370/161/16
VomitingGastrointestinal disorders0/370/370/161/16
Oral herpesInfections and infestations0/370/370/161/16
White blood cell count decreasedInvestigations1/370/371/160/16
Electrocardiogram ST segment abnormalInvestigations0/370/371/160/16
MalaiseGeneral disorders0/370/370/161/16

Baseline characteristics

Safety population included all participants who received at least 1 dose of investigational medicinal product (IMP).

Age, Continuous
Age, Continuous(years)First Test GXR (Fasting), Then Reference GXR (Fasting)First Reference GXR (Fasting), Then Test GXR (Fasting)First Test GXR (Fed), Then Reference GXR (Fed)First Reference GXR (Fed), Then Test GXR (Fed)Total
Mean31.5 ± 8.0033.5 ± 8.7932.6 ± 7.1335.8 ± 11.1533.0 ± 8.55
Sex: Female, Male
Sex: Female, Male(Participants)First Test GXR (Fasting), Then Reference GXR (Fasting)First Reference GXR (Fasting), Then Test GXR (Fasting)First Test GXR (Fed), Then Reference GXR (Fed)First Reference GXR (Fed), Then Test GXR (Fed)Total
Female673319
Male13115534
Race (NIH/OMB)
Race (NIH/OMB)(Participants)First Test GXR (Fasting), Then Reference GXR (Fasting)First Reference GXR (Fasting), Then Test GXR (Fasting)First Test GXR (Fed), Then Reference GXR (Fed)First Reference GXR (Fed), Then Test GXR (Fed)Total
American Indian or Alaska Native00000
Asian19188853
Native Hawaiian or Other Pacific Islander00000
Black or African American00000
White00000
More than one race00000
Unknown or Not Reported00000
08

Study locations

1 site
  • Xuanwu Hospital Capital Medical University
    Beijing, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2018 to primary completion in Nov 2018, 1 month.

Results were first posted in Jan 2020, 1 year 1 month after primary completion.

Of 171 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 10. This study's 1 month is below that.

Counting every sponsor, half of 247 studies reached it within 7 months; a quarter within 3 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 11, 2018
First posted
Jun 25, 2018
StartActual
Oct 11, 2018
Primary completionActual
Nov 28, 2018
CompletionActual
Nov 28, 2018
Results first posted
Jan 9, 2020
Last update
Jan 9, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 9, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03566810
Responsible party
Sponsor
First posted
Jun 25, 2018
Start date
Oct 11, 2018
Primary completion
Nov 28, 2018
Completion
Nov 28, 2018
Results posted
Jan 9, 2020
Last update
Jan 9, 2020

Study contacts

Medical Responsible
study director · Merck Pharmaceutical Manufacturing (Jiangsu) Co., Ltd., an affiliate of Merck KGaA, Darmstadt, Germany

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Metformin

Start the discussion